MP55-10 INCREASED B4GALT7 EXPRESSION IS ASSOCIATED WITH ADVERSE ONCOLOGIC OUTCOME IN LOCALIZED CLEAR CELL RENAL CELL CARCINOMA

Huyang Xie,Zewei Wang,Qiang Fu,Jiejie Xu,Dingwei Ye
DOI: https://doi.org/10.1016/j.juro.2017.02.1703
IF: 7.6
2017-01-01
The Journal of Urology
Abstract:You have accessJournal of UrologyKidney Cancer: Localized: Surgical Therapy III1 Apr 2017MP55-10 INCREASED B4GALT7 EXPRESSION IS ASSOCIATED WITH ADVERSE ONCOLOGIC OUTCOME IN LOCALIZED CLEAR CELL RENAL CELL CARCINOMA Huyang Xie, Zewei Wang, Qiang Fu, Jiejie Xu, and Dingwei Ye Huyang XieHuyang Xie More articles by this author , Zewei WangZewei Wang More articles by this author , Qiang FuQiang Fu More articles by this author , Jiejie XuJiejie Xu More articles by this author , and Dingwei YeDingwei Ye More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2017.02.1703AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES B4GALT7 is one of seven beta-1,4-galactosyltransferase (beta4GalT) genes, which encode type II membrane-bound glycoproteins that appear to have exclusive specificity for the donor substrate UDP-galactose. According to previous studies aberrant B4GALT7 expression has distinct functions in different tumors. Here, we evaluate the association of B4GALT7 expression with oncologic outcomes in patients with localized clear cell renal cell carcinoma (ccRCC) managed by surgery. METHODS A retrospective analysis of 207 and 231 patients with localized ccRCC undergoing RN or NSS at two academic medical centers respectively between 2005 and 2009 was performed. The first cohort with 207 patients was treated as training set and the other as validation set. Tissue microarrays (TMAs) were created in triplicate from formalin-fixed, paraffin embedded specimens. Immunohistochemistry with a commercially available monoclonal B4GALT7 antibody was performed with the intensity (0 to 3) and percentage (0 of 100) of staining recorded. The association of B4GALT7 expression with standard pathologic features and prognosis were evaluated. RESULTS B4GALT7 expression was significantly associated with tumor T stage (P<0.001 and P<0.001, respectively), Fuhrman grade (P<0.001 and P<0.001, respectively) and necrosis (P=0.021 and P=0.002, respectively) in both training and validation sets. Moreover, high B4GALT7 expression indicated poor overall survival (OS) (P<0.001 and P<0.001, respectively) in the two sets. The incorporation of B4GALT7 into T stage and Fuhrman grade would help to refine individual risk stratification. Furthermore, B4GALT7 expression was identified as an independent adverse prognostic factor for survival. CONCLUSIONS Increased B4GALT7 expression is a potential independent adverse prognostic factor for overall survival in patients with localized ccRCC. Inhibiting B4GALT7 pathway might be a promising target of postoperative adjuvant therapy for these ccRCC patients. © 2017FiguresReferencesRelatedDetails Volume 197Issue 4SApril 2017Page: e734 Advertisement Copyright & Permissions© 2017MetricsAuthor Information Huyang Xie More articles by this author Zewei Wang More articles by this author Qiang Fu More articles by this author Jiejie Xu More articles by this author Dingwei Ye More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...
What problem does this paper attempt to address?